Tagged with Pharma,

Austria Barbara Fritsche-Surchat, general manager of Servier Austria, a leading innovative French company looking to bolster its global oncology presence, provides an in-depth analysis of the balancing act between pricing and market access in the Austrian healthcare system as well as how the company’s global oncology vision has influenced Austrian operations.…

Bulgaria Dr. Atanas Atanasov, country manager at Angelini Bulgaria, explains the affiliate’s growth to become a top ten player in the Bulgarian industry and highlights the leadership position of its portfolio in each category based on a long-term promotion strategy and value-based quality. Angelini started its internationalisation process ten years ago,…

Canada Dr. Jeremy B. Desai, CEO & President of Apotex, the Canadian international generics powerhouse, discusses his mandate in 2014 to take the company global, the challenges and opportunities of increasing convergence between the generics, branded and biosimilars sectors globally, and the main growth engines for Apotex looking forward. Jeremy, you…

Tunisia Christophe Sauer, president at Sephire, the association of innovative pharmaceutical companies in Tunisia, talks us through the challenges that innovative MNCs are facing in the country, especially in terms of pricing, but also highlights the important efforts that have been made in public-private dialogues. Mr. Sauer, could you please introduce…

Tunisia The long-awaited conference marking the launch of the company cluster of Sidi Thabet (a city in the governorate of Ariana, 20 minutes from Tunis airport) took place on September 28th 2017 at the Tunis export centre (CEPEX) and revolved around the theme: “Sidi Thabet BioTechpole: serving innovation in the pharmaceutical…

Canada Niven Al-Khoury, President of Sanofi Canada, highlights the strong presence that Sanofi has established in the country over the past 100 years, some of the notable historical achievements from collaboration between Sanofi and Canadian science, as well as the value that Sanofi is committed to bringing to the Canadian healthcare…

Bulgaria Aurélien Breton, general manager at Servier Bulgaria, explains how the affiliate has performed under his tenure and highlights the importance of combining the right portfolio with a top-notch team to successfully navigate the business environment in Bulgaria.  This is your second country management position after Slovenia, and you arrived in…

Tunisia Hatem Hachicha is Pfizer’s former manager for Tunisia, Libya and French-speaking African countries. He believes Tunisia’s pharmaceutical industry development will be achieved through internationalization and a shift towards biosimilars drugs. Co-founder of SEPHIRE and an active member of the Tunisian healthcare community, he stresses that one of the challenges in…

Canada Alok Kanti, president and CEO of Bayer Canada, draws upon his 27 years of international experience with Bayer to discuss the strategic significance of the Canadian affiliate to Bayer’s global operations, the challenges and opportunities he sees for industry-government collaboration, and the need for the country to promote a more…

Canada Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients…

Brazil Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited benchmarking panel focused on operational excellence that has already delivered great outcomes to its members. You were operations vice president…

Canada Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs Inc., his previous company, for CAD 3.2 billion, the cycling accident that left him brain-damaged but more committed than ever…